相关临床试验
109
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1868
进行中（未招募）
2
1.8%
已完成
82
75.2%
尚未招募
4
3.7%
招募中
15
13.8%
终止
2
1.8%
Unknown
3
2.8%
撤回
1
0.9%
暂无批准数据
- A Nature study presents the first genomic analysis of eight Myotis bat species, linking longer lifespans to stronger immune defense and cancer-suppressing gene activity. - Cells from the little brown bat responded to lethal chemical damage by activating cell-death genes rather than DNA repair, mirroring the elephant's anti-cancer strategy. - Researchers found far more overlap than expected by chance between genes associated with bat longevity and genes involved in bat-virus interactions. - Myotis bats show unusual enrichment of genes interacting with DNA viruses such as herpesviruses, a pattern opposite to humans and other primates.
- A UC San Diego and UC Berkeley study published in Science Advances links certain California landscapes to differing Valley fever rates, a fungal infection caused by inhaling Coccidioides spores. - Researchers analyzed 65,657 confirmed Valley fever cases from April 2008 to March 2021, finding shrubland, barren land, grassland, and some crop types associated with higher disease incidence. - Newly fallowed farmland was linked to higher Valley fever rates, with the relationship varying by the land's previous cultivation history. - Findings support dust-control measures and protective measures such as N95 masks as California's landscapes and land use patterns change.
- At least 105 elite American scientists have defected to Chinese institutions since 2024, with nearly half specializing in biotechnology and medicine. - High-profile recruits include Harvard chemist Charles Lieber, Nobel laureate Omar Yaghi, and leading virologist Haitao Hu, drawn by multimillion-dollar funding and advanced laboratories. - China's government R&D spending surged 90% to $133 billion from 2013 to 2023, while the country surpassed the US in clinical trial volume in 2024. - Experts warn the talent exodus threatens US national security and competitive advantage in drug development, as scientists cite fewer regulatory restrictions in China.
- UC Berkeley researchers have mapped the brain circuitry in the hypothalamus that regulates growth hormone release during sleep, published in the journal Cell. - The study reveals a previously unknown feedback loop where growth hormone activates the locus coeruleus to promote wakefulness, but excessive locus coeruleus activity paradoxically induces sleepiness. - During REM sleep, both GHRH and somatostatin increase, driving greater growth hormone release, while non-REM sleep shows a distinct pattern with falling somatostatin and moderately rising GHRH. - The discovery could guide new treatments for sleep disorders linked to diabetes, obesity, cardiovascular disease, and neurodegenerative conditions such as Parkinson's and Alzheimer's disease.
- A deep learning model discovered a previously unrecognized ECG biomarker that identifies patients at high risk of sudden cardiac death, with a 7.0% annual event rate versus 4.6% for reduced LVEF. - The model flagged 86.1% of high-risk patients who were missed by the current LVEF-based standard, and high-risk patients receiving defibrillators showed a 54.4% reduction in mortality. - Validated across three continents (Sweden, USA, Taiwan), the model achieved an AUC of 0.872 in the Swedish lockbox and zero-shot AUCs of 0.822 (USA) and 0.767 (Taiwan). - A generative model visualized the biomarker, revealing a slurred terminal R-wave in lead aVL and axis deviation, suggesting diffuse myocardial fibrosis as a potential underlying mechanism.
- The HER Salt Lake Contraceptive Initiative found that when patients receive person-centered counseling and robust access support, failure rates across most birth control methods narrow to approximately 1 pregnancy per 100 participants per year. - The three-year study of over 4,000 participants challenges the long-held assumption that long-acting reversible contraceptives are vastly superior to shorter-term methods like pills or rings. - Researchers emphasize that respecting patient preferences, providing timely access, and removing logistical barriers are critical to improving real-world contraceptive effectiveness. - The findings suggest that patient-centered care can make preferred methods both acceptable and highly effective, reducing the perceived trade-off between liking a method and needing reliable pregnancy prevention.
- Imperial College London spinout Cardiovolt.ai has raised £1.4 million to commercialize AI models that extract hidden diagnostic signals from standard 10-second ECGs. - The AI achieves 83–93% diagnostic accuracy for heart disease and 70–80% for non-cardiac conditions like diabetes and kidney disease, validated across international datasets. - A separate Nature study from UC Berkeley used 440,000 ECGs to discover a previously unrecognized biomarker for sudden cardiac death invisible to even expert cardiologists. - These advances signal a shift toward combining AI's quantitative intelligence with physicians' qualitative judgment, redefining the future of clinical medicine.
- A Japanese-American woman in her 80s with advanced Alzheimer's disease regained speech, bladder control, and mobility after receiving 5g of psilocybin-containing mushrooms under clinical supervision in Brazil. - Improvements persisted for weeks, and a second 3g dose one month later again enhanced expressiveness, emotional reciprocity, and gait agility. - The authors, led by neuroscientist Marcos Lago from the University of São Paulo, caution that findings do not indicate reversal of Alzheimer's pathology and remain hypothesis-generating only. - The case raises the possibility that latent functional capacities may persist in advanced neurodegeneration and become temporarily accessible under specific neuromodulatory conditions.
- West Coast biotech entrepreneur Lucas Harrington has secured $30 million to launch Preventive, a public-benefit company focused on researching heritable genome editing for disease prevention. - The venture aims to study whether genetically editing embryos can be done safely by correcting harmful mutations or installing beneficial genes, with estimated costs of $5,000 per embryo. - Leading gene-editing experts strongly oppose such ventures, with UC Berkeley's Fyodor Urnov calling them dangerous and misguided distractions from proven therapeutic applications. - Preventive joins two other US startups this year pursuing gene-edited baby technology, though none have gained credibility among mainstream scientists or secured significant research collaborations.
• Glass House Brands has established a research collaboration with UC Berkeley to explore hemp-related applications, including medicinal product development, genetics improvement, and AI automation for cultivation. • The partnership will investigate potential drug development targeting coronaviruses, pain, sleep, inflammation, and cirrhosis, while also evaluating evidence-based approaches to hemp policy and regulation. • With a newly acquired hemp license and R&D greenhouse capacity to produce 240,000 pounds of biomass annually, Glass House positions itself to become one of the largest hemp cultivators in the United States.
